203 related articles for article (PubMed ID: 22198469)
1. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Singh S; Cuzick J; Mesher D; Richmond B; Howell A
Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
[TBL] [Abstract][Full Text] [Related]
2. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
[TBL] [Abstract][Full Text] [Related]
3. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
Cuzick J; Chu K; Keevil B; Brentnall AR; Howell A; Zdenkowski N; Bonanni B; Loibl S; Holli K; Evans DG; Cummings S; Dowsett M
Lancet Oncol; 2024 Jan; 25(1):108-116. PubMed ID: 38070530
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
5. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Jenkins VA; Ambroisine LM; Atkins L; Cuzick J; Howell A; Fallowfield LJ
Lancet Oncol; 2008 Oct; 9(10):953-61. PubMed ID: 18768369
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
Spagnolo F; Sestak I; Howell A; Forbes JF; Cuzick J
J Clin Oncol; 2016 Jan; 34(2):139-43. PubMed ID: 26598748
[TBL] [Abstract][Full Text] [Related]
7. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM
Cancer Nurs; 2009; 32(2):143-50. PubMed ID: 19125120
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
10. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
13. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
[TBL] [Abstract][Full Text] [Related]
15. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
16. Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Mao JJ; Farrar JT; Bruner D; Zee J; Bowman M; Seluzicki C; DeMichele A; Xie SX
Cancer; 2014 Dec; 120(23):3744-51. PubMed ID: 25077452
[TBL] [Abstract][Full Text] [Related]
17. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Altundag K; Dede D; Harputluoglu H; Gullu I
Joint Bone Spine; 2007 Dec; 74(6):662-3. PubMed ID: 17913550
[No Abstract] [Full Text] [Related]
19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Baum M; Budzar AU; Cuzick J; Forbes J; Houghton JH; Klijn JG; Sahmoud T;
Lancet; 2002 Jun; 359(9324):2131-9. PubMed ID: 12090977
[TBL] [Abstract][Full Text] [Related]
20. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Cuzick J
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1377-85. PubMed ID: 18759690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
